Vnitr Lek 2015, 61(1):81-83

Distribution of values of glycated haemoglobin in a population with type 2 diabetes: a project Valetudo

Milan Kvapil
Interní klinika 2. LF UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA

Currently, there are no available data on distribution of the values of glycated haemoglobin in patients with type 2 diabetes in the Czech Republic. More frequent, efficacy and early application of new antidiabetic agents is limited by indication criterion which restricts the payment of this therapy for patients with poorly compensated diabetes defined by threshold value of 60 mmol/mol (6% IFCC). The study Valetudo analyzed distribution of glycated haemoglobin values in the random population of patients with type 2 diabetes and showed that within the critical range from 43 mmol/mol to 80 mmol/mol is the average frequency of patients from the whole population of 1.88%/1 mmol/mol glycated haemoglobin. Interpretation of data from cross-sectional studies is very difficult as they involve patients before treatment (possibly before the intensification of therapy) and also patients successfully treated.

Keywords: diabetes mellitus type 2; distribution of HbA1c; glycated haemoglobin; HbA1c; Valetudo project

Received: November 27, 2014; Published: January 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvapil M. Distribution of values of glycated haemoglobin in a population with type 2 diabetes: a project Valetudo. Vnitr Lek. 2015;61(1):81-83.
Download citation

References

  1. Charvát J, Kvapil M. Vztah terapie hyperglykémie a riziko ischemické choroby srdeční: rok 2010. In: Kvapil M (ed): Diabetologie 2010. Triton: Praha: 2010: 35-57. ISBN 978-80-7387-381-3.
  2. Gerstein HC, Miller ME, Genuth S et al. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364(9): 818-828. Go to original source... Go to PubMed...
  3. Všeobecná zdravotní pojišťovna České republiky. Preskripční omezení. Dostupné z WWW: <http://www.vzp.cz/poskytovatele/ciselniky/preskripcni-omezeni>.
  4. Doležal T, Kvapil M. Kvalita léčby diabetu 2. typu v ČR. In: Kvapil M (ed). Diabetologie 2010. Triton: Praha 2010: 266-282. ISBN 978-80-7387-381-3.
  5. Kvapil M. Projekt Valetudo. Kazuistiky v diabetologii 2010; 8(3): 23-26.
  6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837-853.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.